Glycomine, Inc., A Biotechnology Company Focused On Developing New Therapies For Orphan Diseases, Announced That The Company Has Received Us Food And Drug Administration (Fda) Clearance Of An Investigational New Drug (Ind) Application For Glm101 For The Treatment Of Pmm2-Cdg And Has Initiated Dosing Healthy Volunteers In A Phase 1 Clinical Study. Glm101 Is A Mannose-1-Phosphate Replacement Therapy In Development To Treat Phosphomannomutase 2-Congenital Disorder Of Glycosylation (Pmm2-Cdg), Previously Known As Cdg Type Ia. Pmm2-Cdg Is The Most Prevalent Congenital Disease Of Glycosylation But Has No Fda-Approved Treatments.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!